caa a22 4500 475833740 CHVBK 20180406123848.0 cr unu---uuuuu 170329e20001001xx s 000 0 eng 10.1023/A:1007828804553 doi (NATIONALLICENCE)springer-10.1023/A:1007828804553 Atrial Natriuretic Peptide Reduces the Severe Consequences of Coronary Artery Occlusion in Anaesthetized Dogs [Elektronische Daten] [Mohamed Rastegar, Ágnes Végh, Julius Papp, James Parratt] The aim of the present study was to examine the effects of atrial natriuretic peptide (ANP) on the responses to coronary artery occlusion. In chloralose-urethane anaesthetised mongrel dogs either saline (controls) or human synthetic ANP was infused intravenously (10 μg kg−1 + 0.1 μg kg−1 min−1), starting 30 min before and continuing 10 min during a 25 min occlusion of the left anterior descending coronary artery (LAD). ANP infusion resulted in a fall in mean arterial blood pressure (by 17 ± 2 mmHg, p < 0.05), a transient (max. at 5 min) increase in coronary blood flow (by 24 ± 5 ml min−1, P < 0.05), and a reduction in coronary vascular resistance (by 0.27 ± 0.05 mmHg ml−1, p < 0.05). When the LAD coronary artery was occluded, there was a less marked elevation in left ventricular end-diastolic pressure (LVEDP) in the ANP-treated dogs than in the controls (9.0 ± 0.9 versus 12.2 ± 0.8 mmHg, p < 0.05). Compared to the controls, ANP reduced the number of ventricular premature beats (VPBs, 26 ± 12 versus 416 ± 87, p < 0.05), the number of episodes of ventricular tachycardia per dogs (VT, 0.7 ± 0.3 versus 12.4 ± 4.2, p < 0.05), and the incidences of VT (45% versus 100%, p < 0.05) and ventricular fibrillation (VF 18% versus 57%, p < 0.05) during occlusion. Reperfusion of the ischaemic myocardium at the end of the occlusion period led to VF in all the control dogs (survival from the combined ischaemia-reperfusion insult was therefore 0%), but VF following reperfusion was much less in the dogs given ANP (survival 64%; p < 0.05). The severity of myocardial ischaemia, as assessed from changes in the epicardial ST-segment and the degree of inhomogeneity, was significantly less marked in dogs given ANP. We conclude that ANP protects the myocardium from the consequences of myocardial ischaemia resulting from acute coronary artery occlusion and reperfusion in anaesthetized dogs. Kluwer Academic Publishers, 2000 atrial natriuretic peptide nationallicence arrhythmias nationallicence ischaemia nationallicence myocardial protection nationallicence Rastegar Mohamed Department of Pharmacology and Pharmacotherapy, Albert Szent Györgyi Medical and Pharmacological Center, Szeged University, Dóm tér 12, P.O. Box 427, H-6701, Hungary aut Végh Ágnes Department of Pharmacology and Pharmacotherapy, Albert Szent Györgyi Medical and Pharmacological Center, Szeged University, Dóm tér 12, P.O. Box 427, H-6701, Hungary aut Papp Julius Department of Pharmacology and Pharmacotherapy; Research Unit for Cardiovascular Pharmacology, Hungarian Academy of Sciences, Albert Szent Györgyi Medical and Pharmacological Center, Szeged University, Dóm tér 12, P.O. Box 427, H-6701, Hungary aut Parratt James Department of Pharmacology and Pharmacotherapy, Albert Szent Györgyi Medical and Pharmacological Center, Szeged University, Dóm tér 12, P.O. Box 427, H-6701, Hungary aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/5(2000-10-01), 471-479 0920-3206 14:5<471 2000 14 10557 https://doi.org/10.1023/A:1007828804553 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1007828804553 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Rastegar Mohamed Department of Pharmacology and Pharmacotherapy, Albert Szent Györgyi Medical and Pharmacological Center, Szeged University, Dóm tér 12, P.O. Box 427, H-6701, Hungary aut NATIONALLICENCE 700 1- Végh Ágnes Department of Pharmacology and Pharmacotherapy, Albert Szent Györgyi Medical and Pharmacological Center, Szeged University, Dóm tér 12, P.O. Box 427, H-6701, Hungary aut NATIONALLICENCE 700 1- Papp Julius Department of Pharmacology and Pharmacotherapy; Research Unit for Cardiovascular Pharmacology, Hungarian Academy of Sciences, Albert Szent Györgyi Medical and Pharmacological Center, Szeged University, Dóm tér 12, P.O. Box 427, H-6701, Hungary aut NATIONALLICENCE 700 1- Parratt James Department of Pharmacology and Pharmacotherapy, Albert Szent Györgyi Medical and Pharmacological Center, Szeged University, Dóm tér 12, P.O. Box 427, H-6701, Hungary aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/5(2000-10-01), 471-479 0920-3206 14:5<471 2000 14 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer